Status:
UNKNOWN
Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium
Lead Sponsor:
Sciensano
Collaborating Sponsors:
Pfizer
Merck Sharp & Dohme LLC
Conditions:
Pneumonia
Otitis Media
Eligibility:
All Genders
Brief Summary
The investigators will conduct a prospective observational study of non-invasive S. pneumoniae infections in Belgium and characterize serotype distributions to evaluate national vaccination programs.
Detailed Description
The investigators will conduct a surveillance of non-invasive S. pneumoniae infections in Belgium (September 2020-May 2025). Monthly, 12 peripheral hospitals will send the first 15 unduplicated clinic...
Eligibility Criteria
Inclusion
- Patients living in Belgium at the time of the study,
- from whom unduplicated S. pneumoniae isolates were collected in routine practices,
- from non-invasive upper (e.g.: pus/fluid from nasal sinus or from otitis media fluid) or lower respiratory tract (e.g. sputum bronchial or endotracheal aspirate, bronchoalveolar fluid (BAL),…) clinical samples,
- from patients diagnosed with pneumonia, sinusitis and otitis.
Exclusion
- • Patients for whom S. pneumoniae was simultaneously isolated from blood or another usually sterile specimen
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT04447521
Start Date
September 1 2020
End Date
December 31 2025
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sciensano
Brussels, Belgium, 1180